বিরল রক্তের ক্যান্সার (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different tre…

স্পনসর: Immune Oncology Research Institute
ClinicalTrials.gov-এ NCT05430971
রেজিস্ট্রিতে শেষ আপডেট ৫ জুন ২০২৬ · আমরা পড়েছি ২০ অক্টোবর ২০২৬